



11 May 2022

LungLife AI, Inc.
(the “Company” or “LungLife”)

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a poll.

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Common) TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2021 together with the directors’ and auditor’s reports thereon.	14,321,090	100	0	0	0
Resolution 2 (Common) THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0
Resolution 3 (Common) THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0
Resolution 4 (Common) THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0
Resolution 5 (Common) THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0
Resolution 6 (Common) THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the	14,321,090	100	0	0	0

next Annual General Meeting of the Company.					
Resolution 7 (Common) THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0
Resolution 8 (Common) THAT Crowe LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	14,321,090	100	0	0	0

As at 11 May 2022, there were 25,480,270 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)
Daniel Adams / Virginia Bull / Cameron MacRitchie

Tel: +44 (0)20 7597 5970

Walbrook PR Limited
Paul McManus / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB[®] test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com